Clinical Trials
65 trialsNCT03944304 2026-04-03
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
Asan Medical Center
Phase 2 Completed
NCT04633122 2026-04-03
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT04258956 2025-09-11
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Completed
NCT01907607 2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2 Completed
NCT04282980 2025-03-03
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT00780494 2025-01-14
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Phase 2 Completed
NCT01863745 2024-08-19
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
Phase 2 Completed
NCT01294202 2024-08-02
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT00764595 2023-07-21
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT00769782 2023-07-21
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT02638766 2023-03-27
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT02712112 2023-01-04
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
Phase 2 Completed
NCT02880020 2022-08-18
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02216578 2021-07-15
Ph II CABOGIST in GIST
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00028002 2020-10-26
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT01068769 2020-08-24
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01440959 2020-01-18
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
Asan Medical Center
Phase 2 Completed
NCT02889328 2020-01-09
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Asan Medical Center
Phase 2 Completed
NCT00278876 2020-01-07
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Asan Medical Center
Phase 2 Completed
NCT02607332 2020-01-07
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
Asan Medical Center
Phase 2 Completed
NCT03440515 2020-01-07
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Completed
NCT00568750 2019-06-17
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
Swiss Cancer Institute
Phase 2 Completed
NCT01396148 2019-03-27
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT02606097 2019-03-21
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Chang Gung Memorial Hospital
Phase 2 Completed
NCT00464620 2018-11-23
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT01560260 2018-09-21
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT01243346 2018-06-28
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
Arog Pharmaceuticals, Inc.
Phase 2 Completed
NCT01874665 2018-05-18
GIST
Takeda
Phase 2 Completed
NCT00867113 2018-03-14
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00455559 2018-02-22
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
AEterna Zentaris
Phase 2 Completed
NCT00633295 2017-06-22
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
Novartis
Phase 2 Completed
NCT00112463 2017-06-14
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01172548 2017-05-31
INV555
Novartis
Phase 2 Completed
NCT01524848 2017-05-10
PAGIST
Scandinavian Sarcoma Group
Phase 2 Completed
NCT01831726 2017-03-20
SIGNATURE
Novartis
Phase 2 Completed
NCT01110668 2017-02-28
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00718562 2017-02-23
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
Novartis
Phase 2 Completed
NCT01483014 2016-11-18
CONVERT
Novartis
Phase 2 Completed
NCT01404650 2016-10-04
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01478373 2016-04-27
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Novartis
Phase 2 Completed
NCT01039519 2016-03-10
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Synta Pharmaceuticals Corp.
Phase 2 Completed
NCT00030667 2015-04-15
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
Phase 2 Completed
NCT01267695 2015-02-03
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Peking University
Phase 2 Completed
NCT00237185 2014-08-19
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Novartis
Phase 2 Completed
NCT00254267 2014-02-27
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
Amgen
Phase 2 Completed
NCT00005874 2013-12-04
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00359333 2013-10-30
STS
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT00570635 2013-06-07
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
Exelixis
Phase 2 Completed
NCT00087074 2013-06-04
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed